Physician profile
Vivek Kak
NPI 1821009655
$567.97
in general payments reported to CMS, 2019-2025
10 companies · $43.80 in 2025
The $43.80 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $113 · 2021: $43.76 · 2022: $15.89 · 2023: $14.67 · 2024: $39.88 · 2025: $43.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.65 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.65 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $182.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $141.63 | 2019-2025 | Zerbaxa |
| Insmed, INC. | $80.21 | 2019-2023 | Arikayce |
| Gilead Sciences, INC. | $45.85 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $27.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.51 | 2024 | Entyvio |
| Viiv Healthcare Company | $20.70 | 2021 | |
| Aimmune Therapeutics, INC. | $18.10 | 2025 | Vowst |
| Amgen INC. | $16.37 | 2024 | Krystexxa |
| Abbvie INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Kak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.